Cell culture experiments by Goethe University Frankfurt and the University of Kent corroborate the effectiveness of tecovirimat, cidofovir and brincidofovir – the Frankfurt research group is funded by the Frankfurt Foundation for Children with Cancer
The three antiviral drugs commonly used to treat mpox viruses (monkeypox viruses) are also effective against the viruses from the current outbreak. This has been shown in cell culture experiments by scientists at Goethe University Frankfurt/University Hospital Frankfurt and the University of Kent in Canterbury, Great Britain.
FRANKFURT/CANTERBURY. The mpox virus is closely related to the smallpox virus (variola virus), which caused large, deadly outbreaks before it was eradicated by vaccination at the end of the 1970s. While the smallpox virus led to very severe disease progression with a death rate of about 30 percent, mpox is milder. Nevertheless, the mortality rate is still about three percent. Particularly at risk of a severe course of the disease are people with a weakened immune system, elderly persons, pregnant women, newborn babies and young children. Until recently, mpox outbreaks only occurred in certain parts of Africa when humans became infected through contact with wild animals, typically rodents such as the Gambian pouched rat and the rope squirrel.
However, in May 2022 a first large mpox outbreak outside Africa was detected; the virus spread solely through human-to-human transmission. This ongoing outbreak has so far reached more than 100 countries and been classified by the World Health Organisation (WHO) as a "Public Health Emergency of International Concern".
About 10% of mpox patients require hospital treatment. Moreover, the current mpox outbreak differs from previous ones in terms of both disease transmission and symptoms. These differences raised concerns that the currently circulating mpox virus might have changed in such a way that it would no longer respond to the antiviral drugs available.
Against this backdrop, an international research team led by Professor Jindrich Cinatl from the Institute of Medical Virology, Goethe University Frankfurt/University Hospital Frankfurt, and Professor Martin Michaelis from the School of Biosciences at the University of Kent have succeeded in isolating and cultivating viruses in cell culture from 12 patients from the current mpox outbreak. This has enabled them to test these mpox virus isolates in cultures of skin cells, which has been naturally infected by the mpox virus, for their sensitivity to three drugs presently available to treat the disease: tecovirimat, cidofovir and brincidofovir.
The results showed that all 12 isolates continued to respond to treatment with clinically relevant concentrations of these commonly used drugs.
Professor Jindrich Cinatl said: “We were really concerned that the virus could have changed and become resistant to the available therapies. It is good to see that this is not the case."
Professor Martin Michaelis added: “These findings are very reassuring and give good cause to believe that the antiviral drugs already available will also be effective against the mpox virus in the current outbreak."
The Frankfurt research group “Interdisciplinary Laboratory for Paediatric Tumour and Virus Research", led by Professor Jindrich Cinatl, is funded by the Frankfurt Foundation for Children with Cancer and hosted at the foundation's Dr. Petra Joh Research House.
Publication: Denisa Bojkova, Marco Bechtel, Tamara Rothenburger, Katja Steinhorst, Nadja Zöller, Stefan Kippenberger, Julia Schneider, Victor M. Corman, Hannah Uri, Mark N. Wass, Gaby Knecht, Pavel Khaykin, Timo Wolf, Sandra Ciesek, Holger F. Rabenau, Martin Michaelis, Jindrich Cinatl jr. Drug sensitivity of currently circulating monkeypox viruses. New England Journal of Medicine (2022)
Cinatl Institute of Medical Virology
University Hospital Frankfurt/Goethe University Frankfurt
Tel.: +49 (0)69 6301-6409
Professor Martin Michaelis
School of Biosciences
University of Kent
Tel.: +44 (0)1227 82-7804
Mobile: +44 (0)7561 333 094
Editor: Dr. Markus Bernards, Science Editor, PR & Communication Office, Tel: +49 (0) 69 798-12498, Fax: +49 (0) 69 798-763 12531, email@example.com